A Clinical Review of Noninvasive Tests for Hepatic Fibrosis
- PMID: 39193269
- PMCID: PMC11346005
A Clinical Review of Noninvasive Tests for Hepatic Fibrosis
Abstract
Identifying hepatic fibrosis is paramount in managing patients with chronic liver disease. The etiology of liver disease can be owing to many factors, including chronic viral hepatitis, steatotic liver diseases such as alcohol-associated liver disease or metabolic dysfunction-associated steatotic liver disease, autoimmune hepatitis, and cholestatic liver diseases. Currently, invasive liver biopsy with histopathologic evaluation is the gold standard; however, noninvasive tests are becoming more prevalent, especially because they do not carry the risks of invasive procedures such as biopsy. This article reviews noninvasive tests for fibrosis, separating them into blood-based and imaging-based tests.
Keywords: Chronic liver disease; elastography; hepatic fibrosis; metabolic dysfunction-associated steatotic liver disease; noninvasive tests.
Copyright © 2024, Gastro-Hep Communications, Inc.
Similar articles
-
A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.Eur Radiol. 2024 Jun;34(6):3882-3888. doi: 10.1007/s00330-023-10441-5. Epub 2023 Nov 21. Eur Radiol. 2024. PMID: 37987833
-
Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan).Eur J Gastroenterol Hepatol. 2006 Dec;18(12):1321-5. doi: 10.1097/01.meg.0000243884.55562.37. Eur J Gastroenterol Hepatol. 2006. PMID: 17099382 Review.
-
Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B.World J Gastroenterol. 2014 Sep 14;20(34):12031-8. doi: 10.3748/wjg.v20.i34.12031. World J Gastroenterol. 2014. PMID: 25232240 Free PMC article. Review.
-
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease.Clin Mol Hepatol. 2024 Jun 27. doi: 10.3350/cmh.2024.0246. Online ahead of print. Clin Mol Hepatol. 2024. PMID: 38934108 Review.
-
FibroMeter scores are predictive noninvasive markers of advanced and significant liver fibrosis in patients with chronic viral hepatitis or metabolic dysfunction-associated steatotic liver disease.Ann Gastroenterol. 2023 Nov-Dec;36(6):661-669. doi: 10.20524/aog.2023.0841. Epub 2023 Nov 3. Ann Gastroenterol. 2023. PMID: 38023979 Free PMC article.
References
-
- Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008;12(4):733–746, vii. - PubMed
-
- Salkic NN, Jovanovic P, Hauser G, Brcic M. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol. 2014;109(6):796–809. - PubMed
-
- Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26(5):802–809. - PubMed
LinkOut - more resources
Full Text Sources